Masimo Challenges CBP's Apple Watch Ruling: A Pulse Oximetry Patent Showdown

The ongoing legal dispute between Masimo and the U.S. Customs and Border Protection (CBP) over the importation of Apple Watches epitomizes the complex interplay between intellectual property enforcement and technological innovation. Masimo, a leader in medical technology, is fighting to protect its pulse oximetry patents against what it perceives as unauthorized use by Apple. The crux of the dispute lies in Apple's strategic workaround of an International Trade Commission (ITC) Limited Exclusion Order (LEO) that had previously banned the import of specific Apple Watch models. This workaround involves transferring the pulse oximetry calculations from the watch itself to a paired iPhone. Such moves raise significant questions about the enforcement capabilities of patent protection in a landscape where device functionalities are increasingly distributed across interconnected platforms.

In this contentious environment, the stakes are high for both companies. The ITC's role as a regulatory enforcer is under scrutiny, particularly regarding its ability to address innovations that creatively sidestep patent restrictions. The agency's initial ruling in October 2023 found Apple's application of light‑based pulse oximetry technology to be an infringement on Masimo's patents, marking a significant win for the medical tech firm. However, once Apple altered the functional architecture of its pulse oximetry technology, it exploited a loophole recognized by the CBP, highlighting potential shortcomings in current regulatory frameworks when dealing with rapidly evolving technological landscapes.

Masimo’s legal challenge adds a new dimension to this scenario. By questioning the CBP’s August 2025 ex parte ruling, which permitted the continued import of Apple Watch models under the through‑iPhone processing scheme, the company aims to reconfirm the ITC’s initial findings and prevent what it sees as a dilution of patent enforcement efforts. According to Vital Law, Masimo argues that this scenario, if left unchecked, could set a precarious precedent for future intellectual property disputes, especially in the tech medtech intersection, where the synergy between devices could easily default to gray legal areas.

The patent conflict between Masimo and Apple over the Apple Watch's pulse oximetry feature has become a significant legal battle. Masimo, a renowned medical technology company, is challenging a decision by the U.S. Customs and Border Protection (CBP) in August 2025 that permits the importation of Apple Watch models allegedly infringing on Masimo's pulse oximetry patents. This decision has allowed Apple to continue importing watches that, when paired with iPhones, perform the same pulse oximetry functionalities that were previously banned by the International Trade Commission (ITC) via a Limited Exclusion Order (LEO). Thus, Masimo argues that the CBP's ruling undermines not only the previous ITC decision but also their intellectual property rights..¹

Historically, Masimo’s victory against Apple in October 2023 marked a pivotal moment. The ITC found that Apple's Apple Watch was infringing on Masimo’s light‑based pulse oximetry patents and issued an exclusion order barring imports of those devices. However, Apple countered this order by modifying the technology to transfer the pulse oximetry calculations from the Apple Watch to the paired iPhone, thereby bypassing the ITC's import restrictions without displaying the functionality directly on the watch. Apple's innovative but contentious approach underscores the complex legal and technological challenges at the intersection of intellectual property and digital health product development..¹

Masimo’s complaint against the CBP focuses on the lack of meaningful justification for the reversal of its prior ruling restrictive to Apple's importation. The company alleges that this reversal, which occurred without proper notification to them, effectively nullifies the ITC's photography restriction by allowing devices that still perform the patented functionality through an iPhone connection. This lawsuit not only highlights the intricacies of patent enforcement in the realm of connected devices but also raises questions about the transparency and consistency of enforcement agency decisions in handling such complex cases. More details on Masimo’s legal stance can be found.¹

The Limited Exclusion Order (LEO) issued by the International Trade Commission (ITC) represents a powerful mechanism to combat patent infringement in the United States. Specifically, it serves as an embargo against the importation of products that violate patent rights. This legal tool was exemplified in the case involving Apple and Masimo, where the ITC found that certain Apple Watch models infringed upon Masimo's pulse oximetry patents.,⁵ the ITC's LEO aimed to protect intellectual property by prohibiting these patented technologies' unauthorized entry into the U.S. market, underscoring the order's significance in upholding patent laws.

Apple's response to the ITC's LEO demonstrated the challenges faced in enforcing patents when dealing with integrated technology. By shifting the infringing functionality of pulse oximetry from the Apple Watch to an iPhone, Apple found a loophole to continue offering the feature without directly violating the exclusion order. This tactic effectively exploited a gray area in patent enforcement, showing how technological workarounds can challenge the boundaries of existing trade laws.,⁴ this dispute highlights the complexities faced when enforcing patent protections on interconnected devices.

The August 2025 ruling by the U.S. Customs and Border Protection (CBP) allowed for the continued importation of these watches despite the ITC's earlier decision, raising significant concerns for patent holders like Masimo. Masimo argues that the ruling undermines the ITC's authority and disregards patent protection by permitting products that, in effect, continue to infringe via technological workaround. This decision, criticized for lacking transparency and justification, prompted Masimo to file a lawsuit against the CBP, emphasizing the tension between effective patent enforcement and the fast‑paced evolution of tech integration and design. Fierce Biotech reports on this legal contention and its implications.

This conflict between Masimo and Apple also provides insight into the broader consequences of LEOs and their enforcement. As companies look to ensure their products comply with these orders, creative technological adjustments become a focal point of patent disputes. 9to5Mac notes that such cases may set precedents impacting how future tech products are developed and regulated, highlighting the need for updated frameworks to address functionalities spread across diverse devices.

Apple's strategy to circumvent the Limited Exclusion Order (LEO) imposed by the International Trade Commission (ITC) reflects a significant technological workaround using the interoperability between the Apple Watch and iPhone. When the ITC determined that the Apple Watch infringed on Masimo's pulse oximetry patents, the agency barred Apple from importing these devices into the U.S. To comply with the order without sacrificing the functionality that made the devices desirable, Apple ingeniously moved the processing of blood oxygen data from the watch to the paired iPhone. This allowed Apple to assert that while the watch collects and transmits data, it does not perform the patent‑infringing operations directly. As a result, Apple could continue to import its popular wearables, effectively maintaining their market presence without directly contravening the ITC's ruling.¹

The impact of Apple's workaround is multifaceted, as it touches upon legal, technological, and economic dimensions. Legally, this case showcases how existing patent laws and trade regulations can be tested by the fluid nature of modern technology. By shifting critical functions between different devices, Apple has potentially set a precedent that could influence future import rulings and patent enforcements concerning integrated technologies. Economically, Apple's ability to continue importing its watches underpins their competitive edge in the tech market, potentially affecting rivals like Masimo, who depend on enforcement of their patent rights to protect market share. In broader technological contexts, this underscores a shift where companies might increasingly design their products to legally navigate around patent restrictions, potentially spurring innovation but also leading to complex legal battles.³

The ramifications on patent enforcement and broader regulatory practices are profound. The dispute between Masimo and Apple may compel agencies like the ITC and CBP to rethink how they handle technological workarounds that exploit the interplay between software and hardware across device ecosystems. It shines a light on the necessity for updated trade and patent laws that accommodate digital age complexities. Additionally, the ability for companies to swiftly implement technological changes that circumvent traditional enforcement measures poses significant challenges for regulatory bodies tasked with patent protection. As seen in Masimo's response, there is an ongoing struggle to assert patent rights in an environment where companies like Apple deploy strategic adaptations against exclusionary legal frameworks. This creates an environment ripe for policy discussion on how to balance innovation with adequate protection of intellectual property, as noted in the.⁵

U.S. Customs and Border Protection's (CBP) controversial ex parte ruling, which allows the importation of Apple Watch models that potentially infringe on Masimo's pulse oximetry patents, has drawn significant scrutiny.,¹ this decision contradicts a prior Limited Exclusion Order issued by the International Trade Commission (ITC) that banned such imports over patent infringement concerns. The discrepancy highlights ongoing tensions in balancing trade regulations and patent enforcement, especially when technology companies employ innovative workarounds to bypass restrictions.

The legal battle initiated by Masimo against the CBP centers on allegations that the ruling not only undermines their patent rights but also devalues the ITC's sanctions, risking a precedence where technological modifications could effectively sidestep intellectual property laws. ⁵ argue that this approach by the CBP lacks substantial justification, further agitating stakeholders concerned with maintaining robust patent protections in the U.S.

The reversal by the CBP has been described as ex parte because it was made without notifying Masimo, raising legal concerns about procedural fairness and transparency. Masimo's lawsuit claims that the lack of notification bypassed essential dialogue that might have provided a greater understanding and justification for the ruling. This aspect of the case underscores the importance of transparency and fairness in administrative rulings, especially those that significantly impact ongoing litigation and patent enforcement.

This ongoing dispute is set against the backdrop of Apple’s strategic adaptations to its technology, specifically shifting certain functions from the watch to the iPhone. By moving the blood oxygen calculation process off the watches and onto a paired iPhone, Apple has been able to comply with the letter, if not the spirit, of the import ban. Such tactics are emblematic of the challenges patent holders face in today's rapidly evolving technology landscape, where firmware and hardware integrations blur the lines of infringement.

Moving forward, the outcomes of Masimo's legal challenge could set significant precedents in how cross‑device functionalities are viewed and regulated. Legal experts and industry stakeholders are closely monitoring the case, aware that its implications could ripple across industries, influencing how intellectual property laws adapt to connected, multifunctional consumer products. ⁴ reflects a pivotal moment in the intersection of technology innovation and legal frameworks.

Masimo, recognized for its pioneering work in medical technology, is embroiled in a significant legal confrontation with the U.S. Customs and Border Protection (CBP). The controversy stems from CBP's ex parte ruling that permits Apple to import its contentious Apple Watch models. These models are alleged to infringe upon Masimo’s patents concerning pulse oximetry. This legal maneuver by Masimo is not only a defense of its patented technology but also an assertion of intellectual property rights, pivotal for the company’s ongoing innovation and competitive edge in the med‑tech landscape. The case represents a crucial battleground in the complex terrain where technology, law, and trade enforcement intersect. More details on this development are covered in.¹

The legal duel traces back to an October 2023 ruling by the International Trade Commission (ITC), which determined that certain models of Apple Watch infringed on Masimo’s pulse oximetry patents. The ITC’s decision led to a Limited Exclusion Order (LEO), barring the import of these devices into the U.S. unless they had their pulse oximetry functionalities disabled. Apple's subsequent workaround, through which the calculation of blood oxygen levels is shifted from the watch to a paired iPhone, is a clever, albeit contentious, strategy to comply with the letter of the law while challenging its spirit. This clever reconfiguration has sparked a flurry of legal interpretations and debates, as detailed by.⁴

Masimo's argument against the CBP's latest ruling pivots on the premise that it fundamentally undermines the effectiveness and intent of the ITC's LEO. The company alleges that the CBP’s reversal of its earlier ruling—which allowed Apple Watch imports only under the condition that the infringing feature remains inoperative—was made without proper justification or notice to Masimo. By permitting these imports, Masimo contends, CBP essentially empowered Apple to bypass the regulatory framework designed to protect patent holders. Such a development poses profound implications for the enforcement of trade laws this intersection of technology and regulation, as explored in greater detail at.⁵

This litigation not only reflects Masimo's commitment to its proprietary technology but also highlights broader issues related to patent enforcement in the tech industry. The emergence of interconnected devices wherein functionalities are distributed across multiple products complicates patent law enforcement, setting a challenging precedent for similar disputes in the future. Industry analysts and legal experts are closely watching the outcomes of this case, given that it could materially reshape the frameworks for technological patents and regulatory practices across not only the United States but globally as well. Observers can find a more detailed analysis of the case’s ramifications and potential impacts in.⁶

The legal clash between Masimo and the U.S. Customs and Border Protection (CBP) has sparked a wide range of public reactions and industry perspectives, highlighting the complexities of patent enforcement in the tech‑medical sphere. Advocates for Masimo argue that their commitment to safeguarding intellectual property rights is justified. This stance is especially emphasized within tech and medtech communities, where many see Apple’s workaround—transferring the pulse oximetry calculations from the watch to the iPhone—as a calculated move to evade the International Trade Commission’s Limited Exclusion Order. According to some commentators, this approach seemingly undermines the efforts to maintain the integrity of patent protections in an era of increasingly distributed functionalities.⁴

Conversely, skepticism has been voiced by various observers, including users on social media platforms such as Twitter and Reddit. Some question whether Apple’s design modification constitutes a genuine infringement or is merely a savvy maneuver enabled by gaps in existing patent laws that do not fully account for contemporary connected devices. These voices argue that the CBP’s August 2025 ruling might be a pragmatic acknowledgment of modern technological realities, reflecting a need to adapt patent enforcement to the evolving landscape of integrated device ecosystems.⁶

Across public forums and discussions, there is a notable engagement from professionals in the technology, legal, and intellectual property sectors. Many support Masimo's position as pivotal to ensuring robust protection of patent rights, crucial amid the intricate challenges posed by technology that spans multiple devices. However, some parts of the general public express concerns over potential delays and uncertainties in legal resolutions, which could impact not only consumer access to technology but also innovation in critical medtech segments.⁷

The interplay between Masimo's legal actions and the U.S. Customs and Border Protection (CBP) ex parte ruling could significantly reshape the economic landscape for both medical technology companies and major tech firms like Apple. According to reports, the ability of Apple to continue its importation of the Apple Watch despite patent disputes may lessen potential costs tied to re‑design and litigations, thus enhancing its position in the competitive wearable tech market.

Technologically, the implications are profound as companies may be more inclined to distribute functions across multiple devices to navigate around patent disputes. This strategy, observed in Apple's approach to shift the pulse oximetry calculations from its watch to an iPhone, exemplifies an evolving response to patent infringement challenges. If the CBP's ruling remains unchallenged, this could set a new precedent, emphasizing structural re‑designs to circumvent single‑device patent issues while raising questions about the future of unified user experiences.

Furthermore, the case highlights critical economic and regulatory challenges: the tension between protecting intellectual property and fostering innovation and consumer access. The outcome may set a benchmark for how future digital health technologies are developed—possibly encouraging protective but costly innovations that must navigate a landscape of complex legal restrictions as noted in.⁵

The prospect of heightened regulatory scrutiny and demand for comprehensive enforcement mechanisms may prompt entities like the CBP and ITC to develop new frameworks for multi‑device systems. Such measures could ensure more consistent patent enforcement but may also introduce additional layers of complexity in trade regulations as suggested by experts in.⁴

As we look toward the future of patent enforcement in connected devices, the evolving legal landscape presents both challenges and opportunities. The legal tussle between Masimo and Apple underscores a pivotal shift in how patent rights are interpreted when functionalities can be distributed across multiple devices. Specifically, the Masimo case highlights a pressing need for regulatory bodies like the International Trade Commission (ITC) and the U.S. Customs and Border Protection (CBP) to rethink enforcement strategies in an era where technology products often operate in tandem rather than in isolation. For instance, Apple's decision to offload the pulse oximetry functionality of its Apple Watch to a paired iPhone marked a significant point of contention, effectively questioning the boundaries of traditional patent enforcement (⁵).

The implications of these legal disputes extend beyond the courtroom, affecting economic, social, and technological domains. Economically, the outcome of such cases could redefine how companies approach product innovation, particularly in sectors where technology is perpetually advancing, such as wearable health tech. If patents are too loosely enforced, it could discourage innovation by enabling competitors to adopt similar technologies with minimal consequences. Alternatively, overly stringent enforcement might stifle creativity and invention. Socially, these disputes also affect consumer trust and access to technology. Consumers could be caught in the crossfire if legal roadblocks delay product deliveries or if shortcuts compromise product efficacy and safety, particularly with health‑related features (²).

From a policy perspective, these challenges necessitate an updated approach to trade laws and patent enforcement. There is growing pressure on regulatory bodies to incorporate more sophisticated models of evaluation that consider ecosystems of connected devices rather than focusing on standalone gadgets. Agencies may need to adopt new frameworks that look at functionalities distributed across hardware and software, ensuring that imports meet the intended legal standards. These legal battles will likely influence how patents are drafted, with a possible shift toward favoring modular technological designs to circumvent direct infringement claims. Legal experts suggest that the ongoing dispute between Masimo and the CBP could set crucial precedents for future cases involving device interoperability and software‑dependent functionalities (³).

Furthermore, the intersection of patent law and emerging connected technologies prompts a reevaluation of how intellectual property rights are enforced across borders. As technological advancements blur geographical boundaries, the global nature of trade calls for synchronized efforts among international bodies to manage and resolve these complex issues. This need for international cooperation is evident in cases like Masimo’s, where unilateral decisions by bodies like the CBP can have wide‑reaching implications. The controversy surrounding the Apple Watch’s pulse oximetry function exemplifies the potential for technology to outpace existing legal frameworks, prompting calls for new policies that balance innovation incentives with robust intellectual property protection (⁶).

The ongoing legal battle between Masimo and U.S. Customs and Border Protection (CBP) concerning the importation of Apple Watches may significantly influence trade and innovation across several industries. This case underscores the complexities interwoven in today's interconnected technological landscape, where patents on specific functionalities play a crucial role. By challenging the CBP's ruling that allows Apple to circumvent an import ban, Masimo is not only striving to protect its patents but also spotlighting the potential loopholes that could render trade laws ineffective. According to this report, Masimo's efforts could set a precedent for how intellectual property rights are enforced in the age of rapidly advancing technology.

This dispute exemplifies broader implications for innovation. Suppose the CBP's decision stands without challenge; in that case, it could signal to tech giants that strategic redesigns might suffice to bypass patent restrictions, even if the core function infringes upon existing patents. Such outcomes could deter smaller companies from investing in research and development, fearing that larger corporations might effortlessly navigate around patent rights. This scenario raises important questions about the efficacy of patent enforcement in stimulating technological innovation under current trade laws. Innovation thrives under a passionate pursuit of novel solutions, but when legally enforced protections are undermined, creativity and investment in groundbreaking technologies might suffer.

From a broader trade perspective, the case could influence how global trade agencies approach the enforcement of import bans, especially when functionalities are distributed across multiple devices. The traditional model of patent enforcement might not be suitably equipped to address these challenges, requiring a reevaluation and possible overhaul of existing trade policies. The necessity of updating legal frameworks to align with technological realities is eminent, as highlighted by several analysts who anticipate more sophisticated approaches to managing such disputes. The outcome of Masimo’s legal efforts could potentially guide future policy adjustments, influencing how connected devices are regulated globally.

Overall, the intersection of intellectual property law and technology revealed by Masimo's legal contest with CBP could have profound implications for trade policies and innovation strategies worldwide. The significance extends to influencing consumer access to technologically advanced products and shaping the competitive landscape of the tech industry. As this legal saga unfolds, it is a critical moment for all stakeholders, from policy makers to tech companies, to consider the long‑term impact of current decisions on innovation and international trade dynamics.